Clinical Trial Update: Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating ganitumab (IGF-1R antibody) with dasatinib (SFK inhibitor) in embryonal and alveolar rhabdomyosarcoma was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Rhabdomyosarcoma
• Embryonal Rhabdomyosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Ganitumab (ganitumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-14